Key facts
- It has raised $1.0M across 1 recorded rounds; the latest was Seed Round ($1.0M) in Jun 2021.
- Notable investors include National Institutes of Health, Fox Ventures, National Cancer Institute, North Carolina Biotechnology Center, Small Business Innovation Research and Small Business Technology Transfer Programs — 6 tracked in total.
- Enfuego Therapeutics has filed 1 Form D with the SEC, most recently Jun 2021 ($500K sold to 11 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Enfuego Therapeutics
Funding rounds
1 roundsAbout Enfuego Therapeutics
Operator of a biotech company intended to treat lung, pancreatic, and colon cancers. The company is developing RNA interference-based and antisense oligo therapeutics, enabling healthcare providers to tackle some of the most challenging targets in cancer disease.
- Sector
- Healthcare
- HQ
- Pittsboro, NC, United States
- Founded
- 2019
- Employees
- 2
- Ownership
- Privately Held (backing)
Enfuego Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Enfuego Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Enfuego Therapeutics in its N-PORT filings yet. We sweep new filings monthly.